An investigational migraine treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has returned positive results in three Phase 3 studies. The company says it will now submit a Biologics License Application for galcanezumab to the U.S. Food and Drug Administration later this year. Lilly says it will also turn in additional applications with global regulatory agencies.
Lilly Bio-Medicines President Christi Shaw says "the detailed Phase 3 results presented today represent a crucial step forward for the millions of patients living with migraine who have not yet tried, or found, an effective preventive therapy. Following more than 25 years of research in migraine, Lilly is excited to help usher in a new era of preventive migraine therapies that may substantially improve the current standard of care for people living with migraine."
Lilly also plans to submit study findings to peer-reviewed journals. You can connect to more about the results by clicking here.